Haemonetics Corporation, founded in 1971 by Dr. Allen (Jack) Latham in Natick, Massachusetts, is a global provider of blood and plasma supplies and services. Headquartered in Boston, Massachusetts, the company aims to improve the quality, effectiveness, and efficiency of medical care through innovative technology solutions. Haemonetics offers a range of products and services that optimize operations for plasma centers, enabling higher plasma yield collections and improved productivity and quality.
Notable figures affiliated with Haemonetics include CEO and President Christopher Simon. The company is publicly traded on the NYSE under the ticker HAE and is a component of the S&P 400. With a revenue of $988 million in 2020 and a workforce of 3,300 employees, Haemonetics has made significant strides in the medical devices and healthcare industries. Its impact is evident in its contribution to enhancing patient care through advanced blood management technologies.
